Vatelizumab (Anti-Integrin a2b1 (ITGA2 & ITGB1)) Integrin inhibitor

Name	Citation	Integrin	ILK	Others
Cilengitide trifluoroacetate	70	+++
A-205804	6	++
GLPG0187	1	++++
GSK-3008348 HCl	0	++
Bexotegrast (PLN-74809)	0	+++
Cilengitide	36	+++
OSU-T315	1		+
TR-14035	0	++
Cyclo(RGDyK) TFA	14	++
SB273005	27	++++
RGD (Arg-Gly-Asp) Peptides	26	✔
ILK-IN-3	0		✔
RGD peptide (GRGDNP)	1	✔		caspase-3
ATN-161	22	✔
Cyclo(-RGDfK) TFA	13	✔

Description	Vatelizumab (Anti-Integrin a2b1 (ITGA2 & ITGB1)) is a monoclonal antibody targeting the α2 subunit (CD49b) of very late antigen-2 (VLA-2). It can be used for the research of multiple sclerosis. MW: 144.56 KD.
References	[1] https://pubmed.ncbi.nlm.nih.gov/30783682/

CAS No.	1238217-55-4
Molecular Weight	144.56
Isotype	Human IgG4SP
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100 mM Pro-Ac, 20mM Arg, pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Vatelizumab (Anti-Integrin a2b1 (ITGA2 & ITGB1))